Independent register of U.S. FDA drug recalls · updated Oct 11, 2026
RxRecalls Get alerts

FDA Drug Recalls

14,806 recalls, newest first

Class II · Moderate risk

Menastil

cGMP Deviations

Terminated cGMP deviation Atlantic Management Resources Ltd. NDC 66233-711-01 D-0084-2023
Class II · Moderate risk

ProSirona

cGMP Deviations

Terminated cGMP deviation Atlantic Management Resources Ltd. NDC 66233-712-01 D-0083-2023
Class II · Moderate risk

Neuroquell

cGMP Deviations

Terminated cGMP deviation Atlantic Management Resources Ltd. D-0082-2023
Class II · Moderate risk

Neuroquell Plus

cGMP Deviations

Terminated cGMP deviation Atlantic Management Resources Ltd. D-0081-2023
Class II · Moderate risk

Quinapril Tablets USP

CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.

Terminated Nitrosamine impurity Lupin Pharmaceuticals Inc. NDC 68180-558-09 D-0089-2023
Class II · Moderate risk

Quinapril Tablets USP

CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.

Terminated Nitrosamine impurity Lupin Pharmaceuticals Inc. NDC 68180-554-09 D-0088-2023
Class I · High risk

Advil Liqui Gels

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Terminated Labeling / mix-up Glaxosmithkline Consumer Healthcare Holdings DBA Haleon D-0183-2023
Class I · High risk

Advil Liqui Gels

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Terminated Labeling / mix-up Glaxosmithkline Consumer Healthcare Holdings DBA Haleon D-0182-2023
Class I · High risk

Advil (ibuprofen)

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Terminated Labeling / mix-up Glaxosmithkline Consumer Healthcare Holdings DBA Haleon D-0181-2023
Class III · Low risk

Lacosamide Oral Solution

Failed Excipient Specifications: out of specification result observed for p-Hydroxybenzoic Acid content

Terminated Failed specification Camber Pharmaceuticals, Inc NDC 31722-627-26 D-0094-2023
Class I · High risk

Iohexol (300 mg Iodine/mL)

Labeling: Label Error on Declared Strength: syringes mislabeled as 300 mg iodine/mL contained product 350 mg iodine/mL

Terminated Labeling / mix-up BayCare Integrated Service Center, LLC /dba BayCare Central Pharmacy D-0086-2023
Class I · High risk

8.4% Sodium Bicarbonate Injection

Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration.

Terminated Packaging defect Exela Pharma Sciences LLC NDC 72572-740-20 D-0080-2023
Class I · High risk

8.4% Sodium Bicarbonate Injection

Defective Container: Complaints received of vial breakage and glass flying when pressurized while preparing the product for administration.

Terminated Packaging defect Exela Pharma Sciences LLC NDC 51754-5001-5 D-0079-2023
Class II · Moderate risk

Sensorcaine-MPF

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Terminated Wrong potency / content Fresenius Kabi USA, LLC NDC 63323-468-01 D-0129-2023
Class II · Moderate risk

Sensorcaine

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Terminated Wrong potency / content Fresenius Kabi USA, LLC NDC 63323-463-01 D-0128-2023
Class II · Moderate risk

Sensorcaine

Subpotent Drug: Testing results below the defined limit for the epinephrine portion of this product.

Terminated Wrong potency / content Fresenius Kabi USA, LLC NDC 63323-461-01 D-0127-2023
Class III · Low risk

Allergy Relief D

Failed dissolution specifications

Terminated Dissolution failure Dr. Reddy's Laboratories, Inc. NDC 49032-273-20 D-0073-2023

Recalls by year